What it is: The only naturally occurring cathelicidin in humans, part of the innate immune system's front-line defense against infection, produced by immune cells and skin at sites of injury.
Research suggests: Research demonstrates potent antimicrobial activity, wound healing promotion, immune cell recruitment, and emerging interest in anti-biofilm and anti-cancer mechanisms.
Best for: Immune defense and wound healing researchers
Key thing to know: Functions as both a direct antimicrobial and an immune signaling molecule; naturally produced at sites of infection, making tissue-level context important in research design.
What is LL-37?
LL-37 is a 37-amino-acid cationic peptide and the only cathelicidin found in humans. Cathelicidins are host-defense peptides in the innate immune system's front-line response to infection and tissue damage. LL-37 is derived from the human protein hCAP18, stored inactive in neutrophil granules and cleaved to release active LL-37 at infection sites.
LL-37 is produced by neutrophils, macrophages, natural killer cells, mast cells, and epithelial cells (skin, lung, gut), making it a ubiquitous part of barrier defense. Researchers study it for direct antimicrobial and antiviral activity, immune coordination, wound healing, and biofilm disruption. Reduced LL-37 production is documented in populations with higher infection susceptibility, supporting its role as a host-defense factor.
How it works.
In research, the proposed mechanism has several parts.
A dual mechanism: LL-37 works through a dual mechanism. First, as a direct antimicrobial: its positively charged, amphipathic helical structure binds and disrupts the negatively charged membranes of bacteria, fungi, and enveloped viruses. Because this membrane disruption differs from antibiotics that target specific metabolic pathways, LL-37 retains activity against many antibiotic-resistant organisms.
Immunomodulation: Second, LL-37 acts as an immunomodulatory signal, binding receptors on immune cells such as formyl peptide receptor-like 1 (FPRL1) to coordinate the broader response. Downstream effects include macrophage and neutrophil recruitment, modulation of Toll-like receptor signaling, and stimulation of keratinocyte migration and angiogenesis to support wound healing.
In plain terms: Think of it as both a front-line fighter that eliminates pathogens and a coordinator of the broader immune response. Research also documents LL-37 disrupting bacterial biofilms, the matrices bacteria use to resist antibiotics. Vitamin D regulates LL-37 gene expression, so deficiency is consistently associated with reduced LL-37 production.
What the research shows.
The research evidence breaks down as follows.
Mechanistic evidence: LL-37 has a substantial basic science and mechanistic evidence base documenting its antimicrobial spectrum, membrane-disruption mechanism, and immunomodulatory receptor interactions across multiple independent research groups. The antimicrobial activity against gram-positive bacteria, gram-negative bacteria, and enveloped viruses is well-characterized in vitro. Biofilm disruption activity has been documented against clinically relevant organisms including Pseudomonas aeruginosa and Staphylococcus aureus.
Observational data: Human observational research links LL-37 deficiency to clinical susceptibility: Kostmann syndrome patients (who lack LL-37) suffer severe oral and respiratory infections; cystic fibrosis patients show impaired lung LL-37 activity; and low Vitamin D states, which reduce LL-37 expression, correlate with more respiratory infections. These ground LL-37's relevance in genuine human disease.
Clinical-trial gap: Interventional clinical trial data for exogenous LL-37 administration is growing but limited. Topical LL-37 has been studied in wound healing and venous leg ulcer trials with encouraging results. Systemic administration research in humans is at an earlier stage, with safety and administration parameters still being established.
Biomarkers to review first.
Vitamin D is the most important foundational marker for LL-37 research contexts, its deficiency directly suppresses LL-37 gene expression. Inflammatory and immune baseline markers provide additional context.
What it's commonly researched with.
LL-37 is most often studied in the context of broader immune support protocols, alongside other peptides with immunomodulatory and tissue repair properties. These pairings represent what appears in the research literature, not recommendations for use.